Cargando…

Emerging Treatment Options for Myelofibrosis: Focus on Anemia

Myelofibrosis (MF) is a hematologic malignancy characterized by abnormal proliferation of myeloid cells and the release of pro-inflammatory cytokines, leading to progressive bone marrow dysfunction. The introduction of ruxolitinib just over a decade ago marked a significant advancement in MF therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sastow, Dahniel, Tremblay, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315142/ https://www.ncbi.nlm.nih.gov/pubmed/37404252 http://dx.doi.org/10.2147/TCRM.S386802

Ejemplares similares

CNL and aCML are prognostically distinct: a large National Cancer Database analysis
por: Tremblay, Douglas, et al.
Publicado: (2023)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Anesthesia for the patient undergoing total knee replacement: current status and future prospects
por: Turnbull, Zachary A, et al.
Publicado: (2017)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
por: Naymagon, Leonard, et al.
Publicado: (2017)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Primary myelofibrosis: current therapeutic options
por: de Melo Campos, Paula
Publicado: (2016)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
por: Spampinato, Mariarita, et al.
Publicado: (2021)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone
por: Khan, Afshan A, et al.
Publicado: (2010)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments
por: Tefferi, Ayalew
Publicado: (2017)

Crystallization of lysozyme with (R)-, (S)- and (RS)-2-methyl-2,4-pentanediol
por: Stauber, Mark, et al.
Publicado: (2015)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Treatment Options for Anemia in Kidney Transplant Patients: A Review
por: Bonomini, Mario, et al.
Publicado: (2023)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism
por: Sethi, Sidharth Kumar, et al.
Publicado: (2018)

Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod
por: Kragholm, Kristian, et al.
Publicado: (2015)

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
por: Wang, Hongyu, et al.
Publicado: (2015)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

P1059: REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA
por: Mascarenhas, John, et al.
Publicado: (2023)

New options for the anemia of chronic kidney disease
por: Coyne, Daniel W., et al.
Publicado: (2017)

New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib
por: Koelblinger, Peter, et al.
Publicado: (2018)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Standard care and investigational drugs in the treatment of myelofibrosis
por: Barraco, Daniela, et al.
Publicado: (2019)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1cit8fle2hnn79ofblj045hcp